ADC Therapeutics SA
ADCT
$3.43
-$0.05-1.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -9.47% | 36.36% | -11.03% | 8.21% | 27.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.47% | 36.36% | -11.03% | 8.21% | 27.59% |
| Cost of Revenue | -24.19% | -34.71% | -16.03% | 21.22% | 9.71% |
| Gross Profit | 66.80% | 154.35% | 22.24% | -49.19% | 21.94% |
| SG&A Expenses | 8.63% | 2.72% | -8.03% | -9.41% | -11.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.01% | -18.37% | -12.97% | 7.41% | 0.25% |
| Operating Income | 12.23% | 48.31% | 13.98% | -6.94% | 14.43% |
| Income Before Tax | 14.23% | 78.06% | 6.64% | -52.55% | 17.24% |
| Income Tax Expenses | -- | -25.86% | -- | 435.90% | 1.23% |
| Earnings from Continuing Operations | 14.60% | 79.14% | 6.83% | -55.01% | 17.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.60% | 79.14% | 6.83% | -55.01% | 17.17% |
| EBIT | 12.23% | 48.31% | 13.98% | -6.94% | 14.43% |
| EBITDA | 11.80% | 47.73% | 13.16% | -6.89% | 14.60% |
| EPS Basic | 27.99% | 85.39% | 28.44% | -30.40% | 36.22% |
| Normalized Basic EPS | 28.26% | 88.41% | 28.94% | 2.02% | 35.78% |
| EPS Diluted | 27.99% | 85.39% | 28.44% | -30.40% | 36.22% |
| Normalized Diluted EPS | 28.26% | 88.41% | 28.94% | 2.02% | 35.78% |
| Average Basic Shares Outstanding | 18.62% | 42.61% | 30.17% | 18.87% | 29.86% |
| Average Diluted Shares Outstanding | 18.62% | 42.61% | 30.17% | 18.87% | 29.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |